241 related articles for article (PubMed ID: 31214732)
21. An Ig Transmembrane Domain Motif Improves the Function of TCRs Transduced in Human T Cells: Implications for Immunotherapy.
D'Apice L; Cuccaro F; Varriale S; Cipria D; Sartorius R; Circosta P; Cignetti A; Salerno M; Coscia MR; Oreste U; Marzullo VM; Martini G; Acuto O; De Berardinis P
J Immunother; 2019 May; 42(4):97-109. PubMed ID: 30865026
[TBL] [Abstract][Full Text] [Related]
22. Engineering light-controllable CAR T cells for cancer immunotherapy.
Huang Z; Wu Y; Allen ME; Pan Y; Kyriakakis P; Lu S; Chang YJ; Wang X; Chien S; Wang Y
Sci Adv; 2020 Feb; 6(8):eaay9209. PubMed ID: 32128416
[TBL] [Abstract][Full Text] [Related]
23. Efficient and Non-genotoxic RNA-Based Engineering of Human T Cells Using Tumor-Specific T Cell Receptors With Minimal TCR Mispairing.
Campillo-Davo D; Fujiki F; Van den Bergh JMJ; De Reu H; Smits ELJM; Goossens H; Sugiyama H; Lion E; Berneman ZN; Van Tendeloo V
Front Immunol; 2018; 9():2503. PubMed ID: 30464762
[TBL] [Abstract][Full Text] [Related]
24. T-cells expressing a chimeric-PD1-Dap10-CD3zeta receptor reduce tumour burden in multiple murine syngeneic models of solid cancer.
Parriott G; Deal K; Crean S; Richardson E; Nylen E; Barber A
Immunology; 2020 Jul; 160(3):280-294. PubMed ID: 32144940
[TBL] [Abstract][Full Text] [Related]
25. Development of NKG2D-based chimeric antigen receptor-T cells for gastric cancer treatment.
Tao K; He M; Tao F; Xu G; Ye M; Zheng Y; Li Y
Cancer Chemother Pharmacol; 2018 Nov; 82(5):815-827. PubMed ID: 30132099
[TBL] [Abstract][Full Text] [Related]
26. Current strategies to improve the safety of chimeric antigen receptor (CAR) modified T cells.
Yang QY; Yang JD; Wang YS
Immunol Lett; 2017 Oct; 190():201-205. PubMed ID: 28837818
[TBL] [Abstract][Full Text] [Related]
27. Pharmacologically upregulated carcinoembryonic antigen-expression enhances the cytolytic activity of genetically-modified chimeric antigen receptor NK-92MI against colorectal cancer cells.
Shiozawa M; Chang CH; Huang YC; Chen YC; Chi MS; Hao HC; Chang YC; Takeda S; Chi KH; Wang YS
BMC Immunol; 2018 Aug; 19(1):27. PubMed ID: 30075754
[TBL] [Abstract][Full Text] [Related]
28. Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities.
Shum T; Kruse RL; Rooney CM
Expert Opin Biol Ther; 2018 Jun; 18(6):653-664. PubMed ID: 29727246
[TBL] [Abstract][Full Text] [Related]
29. 3D model for CAR-mediated cytotoxicity using patient-derived colorectal cancer organoids.
Schnalzger TE; de Groot MH; Zhang C; Mosa MH; Michels BE; Röder J; Darvishi T; Wels WS; Farin HF
EMBO J; 2019 Jun; 38(12):. PubMed ID: 31036555
[TBL] [Abstract][Full Text] [Related]
30. Redirecting T-Cell Specificity to EGFR Using mRNA to Self-limit Expression of Chimeric Antigen Receptor.
Caruso HG; Torikai H; Zhang L; Maiti S; Dai J; Do KA; Singh H; Huls H; Lee DA; Champlin RE; Heimberger AB; Cooper LJ
J Immunother; 2016 Jun; 39(5):205-17. PubMed ID: 27163741
[TBL] [Abstract][Full Text] [Related]
31. Preclinical Assessment of CAR T-Cell Therapy Targeting the Tumor Antigen 5T4 in Ovarian Cancer.
Owens GL; Sheard VE; Kalaitsidou M; Blount D; Lad Y; Cheadle EJ; Edmondson RJ; Kooner G; Gilham DE; Harrop R
J Immunother; 2018 Apr; 41(3):130-140. PubMed ID: 29239915
[TBL] [Abstract][Full Text] [Related]
32. Development of a novel target module redirecting UniCAR T cells to Sialyl Tn-expressing tumor cells.
Loureiro LR; Feldmann A; Bergmann R; Koristka S; Berndt N; Arndt C; Pietzsch J; Novo C; Videira P; Bachmann M
Blood Cancer J; 2018 Aug; 8(9):81. PubMed ID: 30190468
[No Abstract] [Full Text] [Related]
33. TCR-based therapy for multiple myeloma and other B-cell malignancies targeting intracellular transcription factor BOB1.
Jahn L; Hombrink P; Hagedoorn RS; Kester MG; van der Steen DM; Rodriguez T; Pentcheva-Hoang T; de Ru AH; Schoonakker MP; Meeuwsen MH; Griffioen M; van Veelen PA; Falkenburg JH; Heemskerk MH
Blood; 2017 Mar; 129(10):1284-1295. PubMed ID: 28053195
[TBL] [Abstract][Full Text] [Related]
34. Making CAR T Cells a Solid Option for Solid Tumors.
Schmidts A; Maus MV
Front Immunol; 2018; 9():2593. PubMed ID: 30467505
[TBL] [Abstract][Full Text] [Related]
35. Chimeric antigen receptor-modified T Cells inhibit the growth and metastases of established tissue factor-positive tumors in NOG mice.
Zhang Q; Wang H; Li H; Xu J; Tian K; Yang J; Lu Z; Zheng J
Oncotarget; 2017 Feb; 8(6):9488-9499. PubMed ID: 28055955
[TBL] [Abstract][Full Text] [Related]
36. Evolution of CD8
Sun Y; Li F; Sonnemann H; Jackson KR; Talukder AH; Katailiha AS; Lizee G
Cells; 2021 Sep; 10(9):. PubMed ID: 34572028
[TBL] [Abstract][Full Text] [Related]
37. Inhibition-Resistant CARs for NK Cell Cancer Immunotherapy.
Zhuang X; Long EO
Trends Immunol; 2019 Dec; 40(12):1078-1081. PubMed ID: 31732285
[TBL] [Abstract][Full Text] [Related]
38. TCR-Like CAR-T Cells Targeting MHC-Bound Minor Histocompatibility Antigens.
Akatsuka Y
Front Immunol; 2020; 11():257. PubMed ID: 32184779
[TBL] [Abstract][Full Text] [Related]
39. Optimization of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma.
Brown CE; Aguilar B; Starr R; Yang X; Chang WC; Weng L; Chang B; Sarkissian A; Brito A; Sanchez JF; Ostberg JR; D'Apuzzo M; Badie B; Barish ME; Forman SJ
Mol Ther; 2018 Jan; 26(1):31-44. PubMed ID: 29103912
[TBL] [Abstract][Full Text] [Related]
40. Rapid Construction of Antitumor T-cell Receptor Vectors from Frozen Tumors for Engineered T-cell Therapy.
Tsuji T; Yoneda A; Matsuzaki J; Miliotto A; Ryan C; Koya RC; Odunsi K
Cancer Immunol Res; 2018 May; 6(5):594-604. PubMed ID: 29588318
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]